March 25th 2025
Under the agreement, AstraZeneca will use Alteogen’s proprietary hyaluronidase platform technology to develop and commercialize subcutaneous formulations of multiple oncology assets in its portfolio.
February 17th 2025
The Role of Bioburden in the Contamination-Control Plan
January 19th 2011A company's contamination-control plan is an important document designed to formalize the rationale, methods, and validation of contamination-control procedures in a manufacturing facility. The author describes the role of bioburden in the contamination-control plan.
Printable Medicines: A Microdosing Device For Producing Personalized Medicines
The authors describe a new method for the production of personalised medicines utilising ultra-precise microdrop printing technology.
Manufacturing Techniques of Orally Dissolving Films
January 2nd 2011The manufacture of orally dissolving films is done by various methods such as solvent casting, hot-melt extrusion, semisolid casting, solid-dispersion extrusion, and rolling. The authors discuss these methods and the various parameters in which dissolving films are evaluated.
Product Differentiation: The Prize for the Winning Drug–Device Combination
November 17th 2010To find out about the regulatory, formulation, and manufacturing considerations involved in developing a new device to deliver a drug, Equipment and Processing Report talked to Paul Wotton, CEO of Antares Pharma.
ODT Market to Exceed $13 Billion by 2015
November 11th 2010The market for orally disintegrating and fast dissolving tablets could exceed revenues of $13 billion by 2015 based on upward global growth trends, according to a report from Technology Catalysts International, a technology transfer and business consulting firm based in Virginia.